Venous thromboembolism risk assessment and prophylaxis in hospitalised medical patients in the Cape Town metropole, South Africa

A Wehmeyer, BPharm; R Coetzee, MPharm, PharmD; J McCartney, MScPharm, PhD

School of Pharmacy, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South Africa

Corresponding author: A Wehmeyer (3470695@myuwc.ac.za)

Background. Venous thromboembolism (VTE) is regarded as the most preventable cause of inpatient death in hospital settings globally. VTE can be prevented through the provision of non-pharmacological and/or pharmacological thromboprophylaxis following individualised risk screening. The Caprini risk assessment model (RAM) offers a validated and well-established approach for VTE risk assessment in medical inpatients. Literature findings describe a trend towards inappropriate and under-prescribing of thromboprophylaxis in this population. Together with concerns regarding clinicians’ perceived importance of VTE risk assessment, the need to clarify these aspects of practice is evident.

Objectives. To describe VTE risk assessment and prophylaxis practices of medical practitioners in public sector hospitals in Western Cape Province, South Africa (SA).

Methods. A retrospective, cross-sectional study design was employed in the medical wards of two district hospitals and one regional hospital in the Cape Town metropole, Western Cape. Medical folders of adult medical inpatients admitted between January and July 2020 were reviewed to assess VTE risk using the Caprini RAM. Thromboprophylaxis therapy prescribed and contraindications to chemoprophylaxis were also evaluated.

Results. Of 380 patients included in the review, 51.6% were female, and the average age was 52.1 years (range 18 - 96); 21.3% had their weight recorded, while none had their height documented. Infectious disease was the predominant diagnosis (49.2%) detected in the sample. Common VTE risk factors identified included bed rest/restricted mobility for <72 hours (76.3%) and serious infection (67.4%). A total of 97.1% of patients (n=369) were found to be at moderate or higher risk of VTE (Caprini score ≥2). Of this at-risk group, 24.1% were eligible to receive chemoprophylaxis, yet no prescription for thromboprophylaxis was identified. Seventy percent of patients (n=266) were prescribed chemoprophylaxis, with enoxaparin accounting for 98.5% of regimens. Contraindications to chemoprophylaxis were recorded in 13.4% of patients.

Conclusions. Although rates of VTE prophylaxis in medical inpatients may be improving, thromboprophylaxis still remains critically underutilised in this population. This study highlighted a consequence of this trend, with inappropriate chemoprophylaxis prescribing becoming more evident. Mechanical prophylaxis prescribing in medical inpatients is lacking, despite the associated benefits. RAMs should be adapted for the SA setting, where infectious diseases are prevalent. Future research should assess RAM use by clinicians, as this could provide insight into improving RAM uptake and thromboprophylaxis prescribing.

S Afr Med J 2022;112(2):117-123. https://doi.org/10.7196/SAMJ.2022.v112i2.16040
guidelines worldwide.[10] The therapeutic practice guideline for VTE developed by the Southern African Society of Thrombosis and Haemostasis closely mirrors the ACCP guideline, which bases VTE risk assessment on the Caprini RAM.[11,12]

SA has one of the greatest dual burdens of tuberculosis (TB) and HIV infection globally, and both infections have well-established relationships with VTE development.[7] In SA, TB was reported to be the leading cause of death in 2017, and disruptions in TB-related care due to the COVID-19 pandemic have been reported.[13] SA has the largest HIV epidemic globally, with 19% of all persons infected with the virus living in that country.[14] TB and HIV are prominent VTE risk factors that are frequently overlooked in the SA setting, and their impact is not well known.[15] A prospective cohort study conducted at Charlotte Maxeke Johannesburg Academic Hospital aimed to investigate the association of VTE with TB and HIV. The authors found that 53.0% and 21.2% of patients presenting with DVT were infected with HIV and TB, respectively.[16]

Low-molecular-weight heparin (LMWH) and unfractionated heparin have proved to be safe, effective and cost-effective agents for VTE prophylaxis in medical inpatients.[11] Mechanical thromboprophylaxis, including intermittent pneumatic compression (IPC) and graduated compression stockings (GCSs), are advocated for use in patients who have contraindications to anticoagulants.[11,12]

Despite growing evidence supporting VTE risk assessment and thromboprophylaxis in medical inpatients, inappropriate and under-prescribing of thromboprophylaxis is evident.[14,16] The multinational survey conducted by Kinge et al.[13] found that only 36.2% of medical inpatients who were at risk for VTE received prophylaxis.[17] In SA, a study investigating thromboprophylaxis in a private hospital group, which included 373 020 patients, found that <25% of at-risk patients received guideline-appropriate interventions.[13]

In SA's public healthcare sector, a lack of adequate data regarding VTE risk assessment and prophylaxis practices in medical inpatients has been reported.[18] Together with the low rate of adherence to VTE clinical practice guidelines, this accentuates the need to clarify these aspects of practice.[18]

**Objectives**
To describe the VTE risk assessment and prophylaxis practices of medical practitioners in public sector hospitals in the Cape Town metropole, Western Cape Province, South Africa.

**Methods**
A quantitative, observational, descriptive, exploratory cross-sectional design was employed in this study. Quantitative data were retrospectively retrieved from patient medical folders in the medical wards of three public sector hospitals (two district hospitals and one regional hospital) in the Cape Town metropole.

Only folders of adult (≥18 years) medical inpatients who were admitted to medical wards between January and July 2020 were included in the study. Patients aged <18 years, surgical patients, and those who required therapeutic anticoagulation for confirmed or suspected VTE, atrial fibrillation, acute coronary syndromes, or any other reason besides VTE prophylaxis were excluded from the study.

The estimated proportion of medical inpatients with VTE in SA was reported to be 57.1%.10 Using this proportion and a two-sided confidence interval of 95% with a ±5% margin of error, a minimum of 377 medical folders needed to be reviewed to achieve an adequate sample size. Length of hospital stay for each patient was calculated in units of 24 hours and reported in days.[15,16]

Convenience sampling was used to recruit hospitals for inclusion in the study, where the first hospitals to respond to the recruitment notice were selected. Patient medical folders were selected using random systematic selection. This was achieved through the randomisation of a list of medical folder numbers obtained from each facility's electronic continuity of care record (eCCR). Patient medical folder numbers were then selected from this list at fixed, periodic intervals, prior to being accessed at each participating hospital.

Data were manually extracted from medical folders with the use of a predesigned data collection tool, which included an updated version of the Caprini RAM.[17] Prior to data collection, the tool was piloted to further inform and refine its design. Patients' individual VTE risk factors were documented, followed by the calculation of their VTE risk score and subsequent VTE risk categorisation according to the Caprini RAM. Inpatient prescription charts were also evaluated to compare thromboprophylaxis prescribed with that recommended by the Caprini RAM. Additional data collected included basic demographic information. Data were then exported to a structured Microsoft Office Excel 2016 spreadsheet (Microsoft, USA), from which analyses were performed.

Descriptive statistics were used to summarise data in the form of percentages and proportions. Student's t-test was used to draw comparisons between means for gender differences in terms of age, weight, height and Caprini VTE risk scores, and p-values <0.05 were regarded as significant.

**Ethical considerations**
Approval to conduct the study was granted by the University of the Western Cape's Biomedical Research Ethics Committee (ref. no. BM20/5/9) and Western Cape Government Health (ref. no. WC_202007_013). Informed consent from patients was not required by the applicable ethics committees because the study was retrospective and lacked direct patient contact, and data were anonymised prior to analysis.

**Results**
The review included 435 medical folders, which were randomly selected from 4 884 medical admissions that were registered on the eCCR database during the 7-month data collection period. Of these, 380 were included in the final sample of the study. Forty-one medical folders were excluded because they did not meet inclusion criteria and 14 folders were excluded owing to missing information.

The patient sample consisted of more females (51.6%) than males (48.4%), with an overall mean age of 52.1 years (Table 1). No significant difference between the mean age of males and females was detected in the sample (p=0.25).

Only 81 patients (21.3%) had a documented weight, but not one record of patient height was documented, so body mass index (BMI) could not be calculated. Among these 81 patients, no statistically significant difference between the mean documented weights was detected between males and females (p=0.94). The average length of stay was calculated at 5.9 days (range 1 - 35), with >80% of patients hospitalised for ≥3 days.

Approximately a quarter of the patients had been hospitalised within 3 months prior to admission. Evidence of recent hospitalisation (≤90 days) is shown in Fig. 1.

The most frequently documented diagnosis was infectious disease (49.2%). This was followed by neurological disease, which accounted for 14.5% of the total sample. Various forms of TB as well as polymerase chain reaction (PCR)-positive and clinically diagnosed/ highly suspected COVID-19 infections accounted for 17.7% and 11.8% of the sample, respectively. Table 2 provides an overview of the diagnoses identified among sampled patients.
Table 1. Demographics of the study population (N=380)

| Gender | n (%) | 18 - 30, n (%) | 31 - 40, n (%) | 41 - 60, n (%) | 61 - 74, n (%) | ≥75, n (%) | Mean (SD) | Minimum | Maximum | Median |
|--------|-------|----------------|----------------|----------------|----------------|-----------|-----------|---------|---------|-------|
| Female | 196 (51.6) | 39 (10.3) | 34 (8.9) | 54 (14.2) | 38 (10.0) | 31 (8.2) | 53.1 (18.0) | 18 | 96 | 55 |
| Male   | 184 (48.4) | 19 (5) | 42 (11.1) | 69 (18.2) | 43 (11.3) | 11 (2.9) | 51.0 (15.3) | 19 | 84 | 52 |
| Total  | 380 (100) | 58 (15.3) | 76 (20.0) | 123 (32.4) | 81 (21.3) | 42 (11.1) | 52.1 (16.8) | 18 | 96 | 54 |

Table 2. Diagnoses in the study population (N=380)

| Primary diagnosis | n (%) |
|-------------------|-------|
| Infectious disease | 187 (49.2) |
| Clinically diagnosed/highly suspected COVID-19 infection* | 7 (1.8) |
| Community-acquired pneumonia | 22 (5.8) |
| Disseminated TB | 20 (5.3) |
| PCR-positive COVID-19 | 38 (10.0) |
| Pulmonary TB | 42 (11.1) |
| TB meningitis | 5 (1.3) |
| Unspecified lower respiratory tract infection | 5 (1.3) |
| Urinary tract infection | 20 (5.3) |
| Other infectious diseases | 28 (7.4) |
| Neurological disease | 55 (14.5) |
| Epilepsy | 9 (2.4) |
| Ischaemic stroke | 21 (5.5) |
| Unspecified stroke | 5 (1.3) |
| Other neurological diseases | 20 (5.3) |
| Gastrointestinal/hepatobiliary disease | 35 (9.2) |
| Acute gastroenteritis | 20 (5.3) |
| Other gastrointestinal/ hepatobiliary diseases | 15 (4.0) |
| Cardiovascular disease | 27 (7.1) |
| Acute decompensated heart failure | 22 (5.8) |
| Other cardiovascular diseases | 5 (1.3) |
| Pulmonary disease | 26 (6.8) |
| Acute exacerbation of COPD | 20 (5.3) |
| Other pulmonary diseases | 6 (1.6) |
| Endocrine/metabolic disease | 17 (4.5) |
| Diabetic ketoacidosis | 10 (2.6) |
| Other endocrine/metabolic diseases | 7 (1.8) |
| Malignancy (active)/haematological disease | 14 (3.7) |
| Bronchogenic carcinoma | 8 (2.1) |
| Other malignancies/haematological diseases | 6 (1.6) |
| Renal disease | 10 (2.6) |
| Acute kidney injury | 7 (1.8) |
| Other renal diseases | 3 (0.8) |
| Psychiatric diseases | 7 (1.8) |
| Drug overdose | 6 (1.6) |
| Other psychiatric diseases | 1 (0.3) |
| Other | 3 (0.8) |

*Clinically diagnosed or high suspicion of COVID-19 based on chest radiograph and clinical examination.

The most common VTE risk factors identified were: (i) patients currently at bed rest/restricted mobility for <72 hours (76.3%); (ii) serious infection that required hospitalisation and antibiotics (67.4%); (iii) age 41 - 60 years (32.9%); and (iv) a personal or family history of genetic or acquired thrombophilia (27.6%).

Other notable risk factors identified in the sample included being non-ambulatory for >72 hours (20.8%) and age 61 - 74 years (20.3%). The distribution of VTE risk factors among sampled patients in relation to the Caprini RAM risk scores is summarised in Table 3.

Following application of the Caprini RAM, 97.1% of patients (n=369) were identified to be at moderate or higher risk of VTE (Caprini score ≥2). No significant difference in Caprini VTE risk scores was detected between males and females (p=0.91). Thromboprophylaxis was prescribed for 71.0% (n=262) of the 369 patients in the at-risk group, for 75.4% (n=180) of the 239 patients in the highest-risk group (Caprini score ≥5), and for 65.9% (n=60) of the 91 patients in the high-risk group (Caprini score 3 - 4). The number of patients in each Caprini risk score category and the rate of thromboprophylaxis prescription are shown in Table 4.

A total of 266 patients (70.0%) were prescribed thromboprophylaxis, in all cases a subcutaneously administered anticoagulant. No prescription for any form of mechanical prophylaxis was documented. Table 5 summarises the initial chemoprophylactic agents prescribed. Enoxaparin was the most commonly prescribed thromboprophylactic agent (98.5% of cases; n=262).

Only 41 of the 266 patients who were prescribed thromboprophylaxis had documented changes to their initial regimen. Twelve percent (n=32) of the sample who were prescribed thromboprophylaxis were switched to an alternative regimen, the majority (n=8) being switched to a lower dose of enoxaparin (20 mg 24-hourly). Three percent (n=9) of those with documented changes had their thromboprophylaxis regimen discontinued entirely. Table 6 displays the altered thromboprophylaxis regimens prescribed.

Contraindications to chemoprophylaxis were recorded in 13.4% of patients in the total sample (n=51). Active bleeding as a contraindication included any documented active haemoptysis,
Table 3. Distribution of VTE risk factors in the study population in accordance with Caprini RAM[^1] (N=380)*

| VTE risk factors score on Caprini RAM | Risk factors, n (% of risk factors) |
|--------------------------------------|-------------------------------------|
| 1 point                              |                                     |
| Age 41 - 60 years                    | 125 (32.9)                          |
| Minor surgery planned (<45 minutes)  | 2 (0.5)                             |
| Past major surgery (>45 minutes)     | 4 (1.1)                             |
| 30 days                              |                                     |
| Visible varicose veins               | 3 (0.8)                             |
| History of inflammatory bowel disease| 0                                   |
| Swollen legs (current)               | 56 (14.7)                           |
| BMI >25 kg/m²                        | 47 (12.4)                           |
| Myocardial infarction                | 2 (0.5)                             |
| Congestive heart failure             | 39 (10.3)                           |
| Serious infection (requires hospitalisation and antibiotic(s)) | 256 (67.4) |
| Chronic respiratory disease, e.g. COPD | 60 (15.8) |
| Currently at bed rest or restricted mobility, including the use of removable leg brace for <72 hours | 290 (76.3) |
| Current use of birth control therapy or hormone replacement therapy | 0 |
| Pregnant or conceived within the past 30 days | 3 (0.8) |
| History of unexplained stillborn infant, recurrent spontaneous abortion (≥23), premature birth with toxemia or growth-restricted infant | 1 (0.3) |
| 2 points                             |                                     |
| Age 61 - 74 years                    | 78 (20.5)                           |
| Current or past malignancies (excluding skin cancer but including melanoma) | 15 (3.9) |
| Planned major surgery lasting longer than 45 minutes (including laparoscopic and arthroscopic) | 5 (1.3) |
| Non-removable plaster cast that prevents leg movement within the past 30 days | 0 |
| Tube in blood vessel in neck or chest that delivers blood or medicine directly to the heart within the last month (e.g. central venous access) | 0 |
| Confined to bed for ≥72 hours (unable to ambulate continuously for 30 feet (9 m) | 79 (20.8) |
| 3 points                             |                                     |
| Age ≥75 years                        | 44 (11.6)                           |
| History of thrombosis: DVT, PE or superficial venous thrombosis | 9 (2.4) |
| Family history of thrombosis (up to third-degree relatives) | 0 |
| Personal or family history of genetic or acquired thrombophilia | 105 (27.6) |
| 5 points                             |                                     |
| Elective major lower extremity arthroplasty | 1 (0.3) |
| Hip, pelvis or leg fracture          | 1 (0.3)                             |
| Multiple trauma                      | 1 (0.3)                             |
| Spinal cord injury with resultant paralysis | 3 (0.8) |
| Stroke                               | 29 (7.6)                            |

Table 4. Risk stratification and thromboprophylaxis prescribed

| Caprini VTE risk score | Patients, n (%) | Patients prescribed thromboprophylaxis, n (%) |
|------------------------|-----------------|---------------------------------------------|
| Low (0 - 1)            | 11 (2.9)        | 4 (1.5)                                     |
| Moderate (2)           | 39 (10.3)       | 22 (8.3)                                    |
| High (3 - 4)           | 91 (23.9)       | 60 (22.6)                                   |
| Highest (≥5)           | 239 (62.9)      | 180 (67.7)                                  |
| Total                  | 380 (100)       | 266 (100)                                   |

VTE = venous thromboembolism.

Table 5. Initial thromboprophylaxis prescribed (N=380)*

| Agent        | Dose    | Frequency | n (%) |
|--------------|---------|-----------|-------|
| Enoxaparin SC| 20 mg   | 24-hourly | 12 (4.5) |
|              | 48-hourly | 1 (0.4)  |
|              | 40 mg   | 24-hourly | 210 (78.9) |
|              | 12-hourly | 3 (1.1)  |
|              | 48-hourly | 1 (0.4)  |
|              | 50 mg   | 24-hourly | 1 (0.4)  |
|              | 60 mg   | 24-hourly | 12 (4.5) |
|              | 12-hourly | 3 (1.1)  |
|              | 80 mg   | 24-hourly | 4 (1.5)  |
|              | 12-hourly | 13 (4.9) |
|              | 100 mg  | 12-hourly | 2 (0.8)  |
| UFH SC       | 5 000 IU | 8-hourly  | 4 (1.5)  |

SC = subcutaneous; UFH = unfractionated heparin.

*Total number of chemoprophylactic agents prescribed = 266.

Table 6. Alternative thromboprophylaxis regimens prescribed (N=32)

| Agent        | Dose    | Frequency | n (%) |
|--------------|---------|-----------|-------|
| Enoxaparin SC| 20 mg   | 24-hourly | 8 (25.0) |
|              | 40 mg   | 24-hourly | 6 (18.8) |
|              | 12-hourly | 2 (6.3)  |
|              | 60 mg   | 12-hourly | 1 (3.1)  |
|              | 80 mg   | 24-hourly | 7 (21.8) |
|              | 12-hourly | 5 (15.6) |
|              | 100 mg  | 12-hourly | 1 (3.1)  |
| UFH SC       | 5 000 IU | 8-hourly  | 2 (6.3)  |

SC = subcutaneous; UFH = unfractionated heparin.

epistaxis, intracranial haemorrhage, including acute subarachnoid haemorrhage and hypertensive thalamic bleed, and/or any form of gastrointestinal bleeding. The most prevalent contraindications were active bleeding during admission and hepatic impairment, which contributed 7.9% and 3.7% to the total sample. A total of 17 patients (4.5%) continued to receive chemoprophylaxis throughout admission despite the presence of documented contraindications to these agents in their medical folders. Contraindications were only detected in 3 patients (0.8%) who were prescribed higher doses of enoxaparin (Table 7).

Of the 7 patients with thrombocytopenia, 3 were prescribed enoxaparin 40 mg 24-hourly throughout admission and only one had their regimen altered, being switched to enoxaparin 80 mg 24-hourly. Of those with hepatic impairment, 3 were prescribed enoxaparin 40 mg 24-hourly and 1 received enoxaparin 20 mg 24-hourly.
Two of the 3 patients who experienced intracranial haemorrhage during admission received enoxaparin 40 mg 24-hourly, while 10 of those who suffered from active bleeding during admission were prescribed enoxaparin 40 mg 24-hourly. Of these 10, 2 had their thromboprophylaxis regimen discontinued entirely and a further 2 were switched to enoxaparin 80 mg and 60 mg 24-hourly, respectively.

Significant renal impairment (creatinine clearance ≤30 mL/min) was noted in 11 patients (2.9%). Of these patients, 4 (1.1%) did not have any form of thromboprophylaxis prescribed, while 6 (1.6%) were prescribed 40 mg enoxaprin 24-hourly and 1 (0.3%) enoxaparin 60 mg 12-hourly. Two patients (0.5%) were switched from enoxaparin 40 mg 24-hourly to 20 mg 24-hourly and 1 (0.3%) was switched to 40 mg 48-hourly.

### Discussion

Appraising VTE risk assessment and prophylaxis practices in medical inpatients is fundamental to understanding the evolution of VTE risk factors and limiting preventable adverse effects and costs associated with inappropriate thromboprophylaxis. Despite the significance of VTE risk assessment and prophylaxis, a paucity of data describing these practices in medical inpatients is evident. The present study therefore aimed to describe these practices in public sector hospitals in the Western Cape. To our knowledge, this study is unique in SA in terms of its evaluation of VTE risk assessment and prophylaxis practices in medical inpatients across multiple public hospitals in the Cape Town metropole. Use of the Caprini RAM to assess VTE risk, correlate risk with recommended thromboprophylaxis, and draw comparisons with what was actually prescribed was also unique in the study setting.

It has been reported that >75% of medical inpatients have multiple risk factors for VTE, resulting in an eight times higher risk than that of the general population. This concept is reflected in our findings, where the majority of our patient sample (97.1%) were determined to be at moderate or higher risk of VTE following objective risk assessment with the Caprini RAM. Similar findings were reported by Shah et al., with 92.7% of patients found to be at a moderate or high risk of VTE using the Caprini RAM, and by a Cameroonian study, in which 94.6% of medical inpatients were found to be at risk using the Caprini RAM. The SA TUNE-IN study compared clinical risk assessment using clinician judgement with objective risk assessment using the Caprini RAM. The authors reported a 13.3% shortfall in the number of patients identified to be at risk for VTE when comparing clinical assessment with the Caprini RAM. Together with our finding that most medical inpatients are at risk for VTE, these results accentuate the need to incorporate structured and validated RAMs into the package of care rendered to medical inpatients.

Obesity (BMI ≥30 kg/m²) has been established as an independent risk factor for VTE development. Numerous studies have demonstrated an approximate doubling in VTE risk in obese patients. In our study, the lack of documented weight (21.3%) and height (0%) in medical folders was concerning in that BMI determination was excluded. Similar findings were reported in a prospective study at Chris Hani Baragwanath Hospital in Johannesburg, where only 3 out of 352 patients had their weight and height measurements documented. After BMI measurement, the authors found that 16.2% of their sample were obese. These findings concerning obesity and the lack of BMI measurement are compounded by our finding that 12.4% of our sample had documented elevated BMI values that were >25 kg/m², yet information required for BMI calculation was lacking. This lack of appreciation for BMI measurement is also evidenced by findings from the TUNE-IN study, where BMI was found to be one of the most overlooked VTE risk factors during risk assessment.

Dosing of LMWHs in certain populations is based on BMI, and a paucity of information to calculate it presents various risks to optimal patient health outcomes, including increased bleeding and ineffectual VTE prophylaxis. Furthermore, pharmacokinetic studies indicate that a weight-based dosing regimen of enoxaparin could be more effective than a standard fixed-dose regimen in morbidly obese medical inpatients. The use of a standardised VTE RAM could serve to circumvent the lack of BMI measurement, as structured RAMs could prompt clinicians to measure BMI as part of standard risk stratification.

Trends in SA hospital admission data have revealed a shift from infectious diseases as the primary diagnoses to non-communicable diseases. In contrast, our study revealed that almost half (49.2%) of our sample had an infectious disease as the diagnosis. However, our finding may be confounded, as the study period included the period during which the SARS-CoV-2 outbreak and subsequent spread of the virus occurred in SA. This postulation is supported by our finding that >10% of the diagnoses identified in our sample were PCR-positive and clinically diagnosed/highly suspected COVID-19 infections. The recently published findings from the first national TB prevalence survey in SA demonstrated a high prevalence of the disease, at 737 per 100 000 persons. Despite the high prevalence of TB in SA and its strong association with thrombosis, neither the Caprini RAM nor the SA VTE prophylactic and therapeutic guidelines include it as an independent risk factor. With regard to TB, the prevalence in our study (17.7%) was similar to that described by De Vries et al., who reported that 17.2% of their sample had active TB. Further, Hodkinson and Mahlangu described TB as the predominant VTE risk factor in patients presenting with new-onset DVT in their study. TB as a risk factor for VTE is reported to be poorly understood, despite its known propensity to induce a hypercoagulable state. The added VTE risk conferred by TB is theorised to be linked to prolonged exposure to systemic inflammation, as opposed to acute infections. The causal relationship between TB and thrombosis has also been linked to the hypercoagulable state identified in patients initiating anti-TB treatment. Although the association of TB with VTE development is evidenced by the literature, various RAMs, including the Caprini RAM, neglect to include it as an independent risk factor. This lack of appreciation for TB infection as an independent risk factor is mirrored by the SA VTE prophylactic and therapeutic guidelines, which only allude to anti-TB treatment use as a VTE risk factor. RAMs used in the SA setting should therefore be adapted to include both TB and anti-TB treatment as VTE risk factors.

HIV infection has a well-established association with thrombosis and consequent VTE development, and the SA VTE prophylactic

| Table 7. Contraindications to chemoprophylaxis (N=380)* | Patients who received chemoprophylaxis throughout admission, n (%) | Patients who were prescribed high doses of enoxaparin,* n (%) |
|--------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Active bleeding during admission                       | Active bleeding during admission | 30 (7.9) | 10 (2.6) | 2 (0.5) |
| Thrombocytopenia (≤100 x 10⁹/L)                        | Thrombocytopenia (≤100 x 10⁹/L) | 7 (1.8) | 3 (0.8) | 1 (0.3) |
| Hepatic impairment (INR >1.5)                          | Hepatic impairment (INR >1.5) | 14 (3.7) | 4 (1.1) | 0 |

*Total contraindications, n=51. Doses of enoxaparin exceeding the standard VTE prophylaxis dose and frequency of 40 mg 24-hourly.
and therapeutic guidelines include HIV infection as a key risk factor, which is noted to confer a high level of VTE risk. Similarly, the Caprini RAM classifies HIV infection under the ‘acquired thrombophilia’ section, and infected patients are categorised as being at high VTE risk even in the absence of other risk factors. In our study, acquired thrombophilia as a VTE risk factor comprised HIV infections only, i.e. 27.6% of our sample were HIV-positive. Similar findings were reported by Du Plooy et al., who found a 29% prevalence of HIV in their sample. The extensive prevalence of HIV and other infectious diseases in SA should ratify VTE RAM adaptation for use in this setting. A pragmatic approach would be to incorporate a separate HIV subsection into a structured RAM, thus improving its utility. Moreover, a conspicuous HIV subsection could lessen the risk of HIV being overlooked during RAM application.

Numerous studies have demonstrated the strong benefit associated with VTE prophylaxis use in at-risk medical inpatients. However, thromboprophylaxis remains underutilised in this patient population. When considering this issue together with the estimation that 75% of hospitalised patients who die from PE are medical inpatients, the need to improve thromboprophylaxis prescribing is clear. Our findings showed that only 71% of patients found to be at moderate or higher risk of VTE with the Caprini RAM were prescribed thromboprophylaxis. Similarly, the SA-based TUNE-IN study reported that 73.5% of medical inpatients in their sample received thromboprophylaxis. Du Plessis et al. had comparable results, with 73.2% of those at risk in their sample receiving thromboprophylaxis with an LMWH. In contrast, the ENDORSE study found that just under half (48%) of medical inpatients in their sample received thromboprophylaxis. Similar findings were reported in a single-centre study in Israel, where 50% of the at-risk patients in the sample received thromboprophylaxis. However, thromboprophylaxis prescription was markedly better in our study compared with findings from the multicentre DissolVE-2 (Identification of Chinese Hospitalized Patients’ Risk Profile for Venous Thromboembolism) study, which found that only 12.9% of medical inpatients received thromboprophylaxis.Comparable results were described by Nkoke et al., who found that only 18.7% of high-risk medical inpatients received thromboprophylaxis across two Cameroonian hospitals. Despite our encouraging findings, 29% of at-risk patients in our sample did not have any form of thromboprophylaxis prescribed. Moreover, almost a quarter (24%) of at-risk patients did not receive thromboprophylaxis despite their lack of contraindications to chemoprophylaxis. On the basis of these findings, it may be construed that thromboprophylaxis prescribing in medical inpatients is expanding. However, a large number of at-risk patients are still overlooked, which may be attributed to a lack of objective RAM use in our setting.

Our finding that enoxaparin 40 mg 24-hourly was prescribed in 89% of our sample was anticipated, as this is the standard thromboprophylaxis regimen in most public healthcare sector hospitals in the Western Cape. Dosing anomalies (doses >40 mg and frequencies differing from 24-hourly) were detected in 15% of patients who were prescribed thromboprophylaxis. Du Plessis et al. reported similar findings, with 17.5% of their sample noted to have received the incorrect dose of an LMWH. These findings may be indicative of a new trend in VTE prophylaxis prescribing, where rates of thromboprophylaxis prescribing in medical inpatients are increasing, but inappropriate dosing is increasing as a consequence. This trend may be further complicated by the inappropriate prescribing of chemoprophylaxis in patients with contraindications, as evidenced by the 4.5% of patients in our sample who received chemoprophylaxis throughout admission. Comparable findings were reported by Rocher et al., who found that 5.6% of patients in their sample were prescribed some form of chemoprophylaxis despite clear contraindications.

Mechanical thromboprophylaxis is a fundamental therapy for preventing VTE in patients with contraindications to anticoagulants, such as active bleeding. The Caprini RAM recommends mechanical prophylaxis as an alternative to chemoprophylaxis in patients at moderate VTE risk and as adjuvant therapy in those considered to be at high and highest risks. No prescription for any form of mechanical thromboprophylaxis was identified. This paucity of mechanical thromboprophylaxis prescribing is worrying, owing to the number of at-risk patients in our sample who had contraindications to chemoprophylaxis and would have benefited from this form of prophylaxis. This lack of mechanical prophylaxis prescribing is further compounded by our finding that 39.2% of patients with documented contraindications to chemoprophylaxis nevertheless had anticoagulants prescribed. However, the possible lack of available mechanical thromboprophylaxis equipment for medical inpatient use may be a factor contributing to these findings. The use of IPC in resource-limited settings such as public healthcare sector hospitals is challenging, as these devices require maintenance to ensure optimal functionality. However, GCs may offer a more feasible approach for use in medical inpatients and require further consideration. The need to improve access to and awareness of mechanical thromboprophylaxis use in medical inpatients is evident from our findings.

**Study limitations**

The retrospective nature of this study is a key limitation, since the quality of data obtained depends on the accuracy and quality of information documented in medical folders. The hospitals selected for this study were all located in the Cape Town metropole, and VTE risk assessment and prophylaxis practices may differ in rural facilities with limited access to specialist clinician consultations.

**Conclusions**

An improvement in the rate of thromboprophylaxis prescribing in medical inpatients is supported by our findings. However, a substantial portion of at-risk patients (29%) are still overlooked in practice, validating the need for extensive appropriation of structured RAMs in the SA public healthcare sector. Furthermore, our study uncovered a consequence of this improvement, where inappropriate dosing of anticoagulants is expanding. The issue of inappropriate dosing of anticoagulants is further complicated by the lack of mechanical prophylaxis prescribing as evidenced by our findings. The use of mechanical prophylaxis should be prioritised to bolster awareness around the benefits of use in patients with contraindications to anticoagulants. TB should be recognised as an independent risk factor for VTE, owing to its propensity to induce thrombosis and its extensive prevalence in SA. Together with HIV, TB and anti-TB treatment should be incorporated into structured RAMs for use in the SA setting. Demarcated subsections for HIV and TB should be incorporated into RAMs to improve utility and convenience of use. The Caprini RAM offers a validated, simplistic and effective approach to VTE risk assessment in medical inpatients. The Caprini RAM may be refined and adapted for specific use in public healthcare sector hospitals in the Cape Town metropole. Novel research should explore reasons underpinning the lack of VTE prophylaxis prescribing and inappropriate prescribing of anticoagulants in medical inpatients.
Declaration. The research for this study was done in partial fulfilment of the requirements for AW’s M Clin Pharm degree at the University of the Western Cape.

Acknowledgements. We acknowledge and thank Yasmine Johnson for her help in accessing healthcare facilities for data collection. We also thank the pharmacy managers at the participating facilities for their logistical and administrative support.

Author contributions. AW conceptualised and designed the study, performed data collection and analysis and drafted the manuscript. RC and JM supervised the study, aided in the design of the study and the data collection tool, and were major contributors to the final manuscript.

Funding. None.

Conflicts of interest. None.

1. Crow M, Dongler N, Kraus ES, et al. Completion of the updated Caprini risk assessment model (2013 version). Clin Appl Thromb Hemost 2019;25(9):1076029619838052. https://doi.org/10.1177/1076029619838052

2. Roche WC, Page T, Roche M, et al. Venous thromboembolism risk and prophylaxis prescription in surgical patients at a tertiary hospital in Eastern Cape Province, South Africa. S Afr Med J 2019;109(3):157-161. https://doi.org/10.7196/SAMJ.2019.v109i10.15150

3. Van der Merwe M, Mjalya M, Du Plessis JM. Is guideline-driven prophylaxis for venous thromboembolism common practice in the South African private hospital setting? J Fam Pract 2020;69(1):e1-e9. https://doi.org/10.4102/safp.v69i1.5022

4. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): A multinational cross-sectional study. Lancet 2008;371(9610):757-764. https://doi.org/10.1016/S0140-6736(08)60202-0

5. Kingue S, Bakilo L, Ze Minkande J, et al. Epidemiological African day for evaluation of patients at risk of venous thromboembolism in adults-standard-treatment-guidelines-and-essential-medicines-list-2nd

6. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon 2005;51(2-3):70-78. https://doi.org/10.1016/j.disamonth.2005.02.003

7. Jacobson BF, Louw S, Riback W. The Use of VTE prophylaxis in relation to patient risk profiling – TUNE-IN study. S Afr Med J 2012;102(22):185-189. https://doi.org/10.7196/SAMJ.4856

8. Minne JG, Kwee YF, Hall RG. Low-molecular-weight heparin prophylaxis dosing: Is weight an issue? J Pharm Technol 2016;42(2):73-80. https://doi.org/10.1371/journal.pone.0235683

9. Romulda MT, Wheeler M, Rodgers GM, et al. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically ill patients. Thromb Res 2010;125(4):220-223. https://doi.org/10.1016/j.thromres.2009.02.003

10. Du Plessis N, Day C, Manning K, et al. Prevalence and outcome of delirium among adult medical inpatients in Cape Town, South Africa. S Afr Med J 2020;110(1):519-524. https://doi.org/10.7196/SAMJ.2020.v110i6.14363

11. Pillay T, Myrus L, Mameta L, Damnit A. What did we learn from South Africa’s first-ever tuberculosis prevalence survey? S Afr Med J 2021;113(5):402-404. https://doi.org/10.7196/SAMJ.2021.v113i5.16562

12. Du Plessis JA, van Blydenstein SA, Wong M. Evaluation of the use of low-molecular-weight heparin for venous thromboembolism prophylaxis in medical patients. S Afr Med J 2021;110(3):235-242. https://doi.org/10.7196/SAMJ.2020.v110i3.14279

13. Skok N, Westergard J. Recommendations for VTE prophylaxis in medically ill patients. Ann Vasc Dis 2020;13(1):38-44. https://doi.org/10.3400/avd.ra.19-00115

14. Shah SS, Abdi A, Oncem P, et al. The rational use of thromboembolism therapy in hospitalised patients and the perspectives of healthcare providers in Northern Cyprus. Phleb ONE 2020;11(7):e280-285. https://doi.org/10.1371/journal.pone.0235495

15. Roche WC, de Vries E. Multidisciplinary in a large district hospital: A descriptive cross-sectional study. S Afr Med J 2017;107(11):1119-1122. https://doi.org/10.7196/SAMJ.2017.v107i11.12443

16. Nikole C, Thelma Ngport M, Atemang E, et al. Incidence of venous thromboembolism, risk factors and prophylaxis in hospitalised patients in the south west of Cameroon. Vasc Health Risk Manag 2020;16:317-324. https://doi.org/10.2147/VHRM.S203935

17. Kane ADS, Biju JP, Narusri JR, et al. Body size measures and risk of venous thromboembolism: Protocol for a systematic review and meta-analysis. BMJ Open 2018;8(3):e019858. https://doi.org/10.1136/bmjopen-2017-019858

18. Kloueva J, Bess M, Nordendgard BG. Obesity as a causal risk factor for deep venous thrombosis. A Mendelian randomization study. J Intern Med 2015;277(5):579-584. https://doi.org/10.1111/j.1365-2702.2015.02299.x

19. Minne JG, Kwee YF, Hall RG. Low-molecular-weight heparin prophylaxis dosing: Is weight an issue? J Pharm Technol 2016;42(2):73-80. https://doi.org/10.1371/journal.pone.0235683

20. Romulda MT, Wheeler M, Rodgers GM, et al. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically ill patients. Thromb Res 2010;125(4):220-223. https://doi.org/10.1016/j.thromres.2009.02.003

21. Du Plessis N, Day C, Manning K, et al. Prevalence and outcome of delirium among adult medical inpatients in Cape Town, South Africa. S Afr Med J 2020;110(1):519-524. https://doi.org/10.7196/SAMJ.2020.v110i6.14363

22. Pillay T, Myrus L, Mameta L, Damnit A. What did we learn from South Africa’s first-ever tuberculosis prevalence survey? S Afr Med J 2021;113(5):402-404. https://doi.org/10.7196/SAMJ.2021.v113i5.16562

23. Du Plessis JA, van Blydenstein SA, Wong M. Evaluation of the use of low-molecular-weight heparin for venous thromboembolism prophylaxis in medical patients. S Afr Med J 2021;110(3):235-242. https://doi.org/10.7196/SAMJ.2020.v110i3.14279